Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

Masking and Visitation Changes: Due to high rates of respiratory illnesses in our community, we’ve made changes to our masking and visitation guidelines .

Current Research Studies

A PHASE II RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFECT OF GLCNAC ON TEAR PRODUCTION IN INDIVIDUALS WITH NGLY1-CDDG

NGLY-1 Trial

Phase: II
Clinicaltrials.gov ID: NCT05402345

What is the goal of the study?

Patients with NGLY1-CDDG will be randomly assigned in a 1:1 ratio to receive either N-acetylglucosamine (GlcNAc) or placebo 3 times per day for 6 weeks. The primary efficacy endpoint is change in tear production between baseline and 6 weeks as measured by the Schirmer II test.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Christina Lam
Study Team Member: Seishu Horikoshi, [email protected]

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.